Frontiers of Medicine
doi:10.1007/s11684-023-0996-8
Abstract:
Here, we discovered that BGB-A445, a non-ligand-competitive agonistic anti-OX40 antibody currently underIn addition, BGB-A445 dose-dependently and significantly depleted regulatory T cells in vitroIn the MC38 syngeneic model established in humanized OX40 knock-in mice, BGB-A445 demonstrated robustFurthermore, BGB-A445 demonstrated a strong combination antitumor effect with an anti-PD-1 antibody.Taken together, our findings show that BGB-A445, which does not block OX40–OX40L interaction in contrast